[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI:3322/caac.21492.
|
[2] |
Desantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state[J]. CA Cancer J Clin, 2017, 67(6): 439-448. DOI: 10.3322/caac.21412.
|
[3] |
Chen CQ, Chen CS, Chen JJ, et al. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer[J]. Mol Cell Biochem, 2013, 383(1-2): 137-148. DOI: 10.1007/s11010-013-1762-z.
|
[4] |
Wang XX, Xu J, Wang H, et al. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells[J]. Biochem Biophys Res Commun, 2015, 456(1):320-326. DOI: 10.1016/j.bbrc.2014.11.079.
|
[5] |
Liu JB, Li Y. Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway[J]. Biochem Biophys Res Commun, 2015, 467(2): 242-247. DOI: 10.1016/j.bbrc.2015.09.182.
|
[6] |
Davis KG, Orangio GR. Basic Science, Epidemiology, and Screening for Anal Intraepithelial Neoplasia and Its Relationship to Anal Squamous Cell Cancer[J]. Clin Colon Rect Surg, 2018, 31(6): 368-378. DOI: 10.1055/s-0038-1668107.
|
[7] |
Yang F, Shan P, Zhao N, et al. Development of hydroxamate based histone deacetylase inhibitors containing 1,2,4-oxadiazolemoiety core with antitumor activities[J]. Bioorg Med Chem Lett, 2018, 10(19): 51-57. DOI:10.1016/j.bmcl.2018.11.027.
|
[8] |
Lin WC, Hsu FS, et al. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma[J]. J Mol (Berl), 2018, 96 (12): 1307-1318. DOI: 10.1007/s00109-018-1697-7.
|
[9] |
Cappellacci L, Perinelli DR, Maggi F, et al. Recent progress in histone deacetylase inhibitors as anticancer agents[J]. Curr Med Chem, 2018, 11(6): 10-17. DOI: 10.2174/0929867325666181016163110.
|
[10] |
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights[J]. Pharmacol Ther, 2014, 143(3): 323-336. DOI:10.1016/j.pharmthera.2014.04.004.
|
[11] |
Cheng WW, Zhang DM. Design, synthesis and biological evaluation of novel HDAC inhibitors: sulphur-containing zinc binding groups[J]. J Chin Pharmaceutical Sci, 2019, 28(06): 408-421. DOI: 10.1016/j.ejmech.2020.112648.
|
[12] |
孟瑾,刘新利,车玲等. 组蛋白去乙酰化酶抑制剂TSA抑制结肠癌HT29细胞增殖作用的机制研究[J].消化肿瘤杂志(电子版), 2019, 11(02): 88-93. DOI: 10.3969/j.issn.1674-7402.2019.02.005.
|
[13] |
Martínez-León E, Amable G, Jácamo R, et al. Protein kinase D1 inhibition interferes with mitosis progression[J]. J Cell Physiol, 2019, 234(11): 20510-20519. DOI: 10.1002/jcp.28651.
|
[14] |
Hamzeloo-Moghadam M, Aghaei M, Abdolmoham Madi MH, et al. Anticancer activity of britannin through the downregulation of cyclin D1 and CDK4 in human breast cancer cells[J]. J Cancer Res Ther, 2019, 15(5): 1105-1108. DOI: 10.4103/jcrt.JCRT_517_17.
|
[15] |
Park HS, Hwang HJ, Kim GY, et al. Induction of apoptosis by fucoidan in human leukemia U937 cells through activation of p38MAPK and modulation of Bcl-2 family[J]. Mar Drugs, 2013, 11(7): 2347-2364. DOI: 10.3390/md11072347.
|
[16] |
Zhou XC, Jiang WB, Liu ZS, et a1. Virus in fection and death receptor-mediated apoptosis[J].Viruses, 2017, 9(11): 316-334. DOI: 10.3390/v9110316.
|
[17] |
Liu YT, Hsieh MJ, Lin JT, et al. Erianin induces cell apoptosis through ERK pathway in human nasopharyngeal carcinoma[J]. Biomed Pharmacother, 2019, 111(3): 262-269. DOI: 10.1016/j.biopha. 2018. 12. 081.
|
[18] |
Burotto M, Chiou VL, Lee J, et al.The MAPK pathway across different malignancies: A new perspective[J]. Cancer, 2015, 120(22): 3446-3456. DOI: 10.1002/cncr.28864.
|
[19] |
Xue B,Wu W,Huang K,et al. Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by ανβ6 integrin-mediated signaling in ovarian cancer[J]. Mol Cell Biochem,2013, 380(1/2): 177-184. DOI: 10.1359/jbmr.2003.18.8.1404.
|
[20] |
Zhang H, Zhao X, Liu HB, et al. Trichostatin A inhibits proliferation of PC3 prostate cancer cells by disrupting the EGFR pathway[J]. Oncol Lett, 2019, 18(1): 687-693. DOI: 10.3892/ol.2019.10384.
|